Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer

Marijke Bontenbal; M Andersson; J Wildiers; G Cocconi; J Jassem; R Paridaens; N Rotmensz; R Sylvester; HT Mouridsen; Jan Klijn; AT van Oosterom

Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer

Marijke Bontenbal
, M Andersson
, J Wildiers
, G Cocconi
, J Jassem
, R Paridaens
, N Rotmensz
, R Sylvester
, HT Mouridsen
, Jan Klijn
, AT van Oosterom

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

54 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	2257-2263
Number of pages	7
Journal	British Journal of Cancer
Volume	77
Issue number	12
Publication status	Published - 1998

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC 04-01-DD-01-01

Cite this

@article{12c63f37b4944745815af9ea4a57ee32,

title = "Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer",

author = "Marijke Bontenbal and M Andersson and J Wildiers and G Cocconi and J Jassem and R Paridaens and N Rotmensz and R Sylvester and HT Mouridsen and Jan Klijn and \{van Oosterom\}, AT",

year = "1998",

language = "Undefined/Unknown",

volume = "77",

pages = "2257--2263",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "12",

}

TY - JOUR

T1 - Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer

AU - Bontenbal, Marijke

AU - Andersson, M

AU - Wildiers, J

AU - Cocconi, G

AU - Jassem, J

AU - Paridaens, R

AU - Rotmensz, N

AU - Sylvester, R

AU - Mouridsen, HT

AU - Klijn, Jan

AU - van Oosterom, AT

PY - 1998

Y1 - 1998

M3 - Article

SN - 0007-0920

VL - 77

SP - 2257

EP - 2263

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 12

ER -